West Pharmaceutical Services (WST) Cost of Revenue (2009 - 2026)

West Pharmaceutical Services has disclosed Cost of Revenue across 18 years of filings, most recently posting $548.5 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $548.5 million, up 17.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 8.28% YoY), and the FY2025 annual result was $2.0 billion, up 3.98% from the prior year.
• Cost of Revenue came in at $548.5 million for Q1 2026 at West Pharmaceutical Services, up from $501.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $548.5 million in Q1 2026 to a low of $418.9 million in Q3 2022.
• The 5-year median for Cost of Revenue is $465.2 million (2024), against an average of $469.7 million.
• Across the five-year window, Cost of Revenue gained 0.14% in 2022 and grew 17.68% in 2026, its largest moves.
• West Pharmaceutical Services' Cost of Revenue stood at $446.6 million in 2022, then increased by 1.61% to $453.8 million in 2023, then advanced by 4.72% to $475.2 million in 2024, then gained by 5.45% to $501.1 million in 2025, then grew by 9.46% to $548.5 million in 2026.
• The last three Cost of Revenue figures came in at $548.5 million (Q1 2026), $501.1 million (Q4 2025), and $510.3 million (Q3 2025), per Business Quant data.